-
1دورية أكاديمية
المؤلفون: Charleer, Sara, de Block, Christophe, Nobels, Frank, Radermecker, Regis P., Lowyck, Ine, Mullens, Annelies, Scarniere, Denis, Spincemaille, Katrien, Strivay, Marie, Weber, Eric, Taes, Youri, Vercammen, Chris, Keymeulen, Bart, Mathieu, Chantal, Gillard, Pieter
المساهمون: RESCUE Trial Investigators
المصدر: 0149-5992 ; Diabetes care
مصطلحات موضوعية: Human medicine
الوصف: OBJECTIVE In recent years, a growing number of people with type 1 diabetes gained access to real-time continuous glucose monitoring (rtCGM). Long-term benefits of rtCGM are unclear because of a lack of large studies of long duration. We evaluated whether real-world rtCGM use up to 24 months offered benefits, particularly in those living with impaired awareness of hypoglycemia (IAH). RESEARCH DESIGN AND METHODS This 24-month, prospective, observational cohort study followed 441 adults with insulin pumps receiving full reimbursement for rtCGM. Forty-two percent had IAH. The primary end point was evolution of HbA(1c), with secondary end points change in acute hypoglycemia complications, diabetes-related work absenteeism, and quality of life scores. Additionally, we evaluated whether people could achieve glycemic consensus targets during follow-up. RESULTS After 24 months, HbA(1c) remained significantly lower compared with baseline (7.64% [60 mmol/mol] vs. 7.37% [57 mmol/mol], P < 0.0001). Sustained benefits were also observed for the score on the hypoglycemia fear survey and hypoglycemia-related acute complications irrespective of hypoglycemia awareness level. People with IAH had the strongest improvement, especially for severe hypoglycemia (862 events in the year before vs. 119 events per 100 patient-years in the 2nd year, P < 0.0001). Over 24 months, more people were able to meet hypoglycemia consensus targets at the expense of slightly fewer people achieving hyperglycemia consensus targets. Furthermore, the number of people with HbA(1c) <7% (<53 mmol/mol) without severe hypoglycemia events more than doubled (11.0% vs. 25.4%, P < 0.0001). CONCLUSIONS Use of rtCGM led to sustained improvements in hypoglycemia-related glucose control over 24 months. Lower fear of hypoglycemia, fewer acute hypoglycemia-related events, and fewer diabetes-related days off from work were observed, particularly in those with IAH.
العلاقة: info:eu-repo/semantics/altIdentifier/isi/000590854800026
-
2دورية أكاديمية
المؤلفون: Charleer, Sara, De Block, Christophe, Nobels, Frank, Radermecker, Regis P., LOWYCK, Ine, Mullens, Annelies, Scarniere, Denis, Spincemaille, Katrien, Strivay, Marie, Weber, Eric, Taes, Youri, Vercammen, Chris, Keymeulen, Bart, Mathieu, Chantal, Gillard, Pieter
المساهمون: Gillard, Pieter/0000-0001-9111-4561, Keymeulen, Bart/0000-0002-8671-4527, Mathieu, Chantal/0000-0002-4055-5233, Charleer, Sara/0000-0003-2100-4927
الوصف: OBJECTIVE In recent years, a growing number of people with type 1 diabetes gained access to real-time continuous glucose monitoring (rtCGM). Long-term benefits of rtCGM are unclear because of a lack of large studies of long duration. We evaluated whether real-world rtCGM use up to 24 months offered benefits, particularly in those living with impaired awareness of hypoglycemia (IAH). RESEARCH DESIGN AND METHODS This 24-month, prospective, observational cohort study followed 441 adults with insulin pumps receiving full reimbursement for rtCGM. Forty-two percent had IAH. The primary end point was evolution of HbA(1c), with secondary end points change in acute hypoglycemia complications, diabetes-related work absenteeism, and quality of life scores. Additionally, we evaluated whether people could achieve glycemic consensus targets during follow-up. RESULTS After 24 months, HbA(1c) remained significantly lower compared with baseline (7.64% [60 mmol/mol] vs. 7.37% [57 mmol/mol], P < 0.0001). Sustained benefits were also observed for the score on the hypoglycemia fear survey and hypoglycemia-related acute complications irrespective of hypoglycemia awareness level. People with IAH had the strongest improvement, especially for severe hypoglycemia (862 events in the year before vs. 119 events per 100 patient-years in the 2nd year, P < 0.0001). Over 24 months, more people were able to meet hypoglycemia consensus targets at the expense of slightly fewer people achieving hyperglycemia consensus targets. Furthermore, the number of people with HbA(1c) <7% (<53 mmol/mol) without severe hypoglycemia events more than doubled (11.0% vs. 25.4%, P < 0.0001). CONCLUSIONS Use of rtCGM led to sustained improvements in hypoglycemia-related glucose control over 24 months. Lower fear of hypoglycemia, fewer acute hypoglycemia-related events, and fewer diabetes-related days off from work were observed, particularly in those with IAH. ; S.C. received a doctoral grant for strategic basic research and P.G. received a grant for a ...
العلاقة: DIABETES CARE, 43 (12) , p. 3016 -3023; http://hdl.handle.net/1942/33162Test; 3023; 12; 3016; 43; WOS:000590854800026
-
3دورية أكاديمية
المؤلفون: Charleer, S., De Block, C., Radermecker, R., Weber, E., Vercammen, C., Strivay, M., Scarniere, D., Taes, Y., Spincemaille, K., LOWYCK, Ine, Mullens, A., Crenier, L., Van Huffel, L., Nobels, F., Keymeulen, B., Mathieu, C., Gillard, P.
الوصف: Background and Aims: Long‐term real‐world studies on the use of glucose sensors are scarce. This study evaluates the impact of real‐time continuous glucose monitoring (RT‐CGM) reimbursement in adults with type 1 diabetes (T1D) who use continuous subcutaneous insulin infusion (CSII) in Belgium. Methods: Data from this 24‐month, prospective, real‐world study were collected between September 2014 and December 2018. Main endpoints were evolution of HbA1c, hospitalisations for hypoglycaemia and ketoacidosis, quality of life, and time in ranges. Data are mean (95% CI). Results: Of 515 people, 82 (16%) stopped using RT‐CGM, mainly because of alarm fatigue (n = 27). Baseline HbA1c decreased from 7.7% (7.5–7.8) to 7.4% (7.2–7.5) at 12 months and remained stable for 24 months (p < 0.001 for both). In participants with baseline HbA1c >8.0%, HbA1c dropped from 8.8% (8.6–8.9) to 8.1% (7.9–8.2) at 24 months (p < 0.001), while it increased from 6.5% (6.4–6.6) to 6.7% (6.5–6.8) (p < 0.001) in participants with baseline HbA1c <7.0%. One year before reimbursement, 15% of participants were hospitalised for hypoglycaemia or ketoacidosis in contrast to 4% in year 1 and 3% in year 2 (p < 0.001 for both). The worry subscale of the Hypoglycaemia Fear Survey improved (18.2 [16.8–19.5] at baseline; 14.0 [12.6–15.3] after 24 months; p < 0.001). Time <54 mg/dL and <70‐≥54 mg/dL significantly decreased from 1.2% (1.0–1.4) and 3.7% (3.3–4.2) in the first two weeks to respectively 0.9% (0.7–1.0) and 2.8% (2.4–3.2) after 24 months (p < 0.001). Conclusions: RT‐CGM reimbursement for adults with T1D on CSII results in improved glycaemic control and quality of life, with fewer diabetes‐related hospitalisations, which is sustained over 24 months.
العلاقة: DIABETES TECHNOLOGY & THERAPEUTICS, 22 (S1) , p. A122 -A123 (Art N° Meeting abstract 275); http://hdl.handle.net/1942/30832Test; A123; S1; A122; 22; WOS:000514025300312; http://doi.org/10.1089/dia.2020.2525.abstractsTest
-
4
المؤلفون: RESCUE trial investigators, Charleer, Sara, De Block, Christophe, Nobels, Frank, Radermecker, Regis P, Lowyck, Ine, Mullens, Annelies, Scarnière, Denis, Spincemaille, Katrien, Strivay, Marie, Weber, Eric, Taes, Youri, Vercammen, Chris, Keymeulen, Bart, Mathieu, Chantal, Gillard, Pieter
المساهمون: Pathology/molecular and cellular medicine, Diabetes Pathology & Therapy, Diabetes Clinic, RESCUE Trial Investigators
المصدر: Diabetes care
مصطلحات موضوعية: Blood Glucose, Male, Time Factors, endocrine system diseases, type 1 diabetes, medicine.medical_treatment, Endocrinology, Diabetes and Metabolism, Cohort Studies, 0302 clinical medicine, Surveys and Questionnaires, Insulin, 030212 general & internal medicine, Prospective Studies, Prospective cohort study, Fear, Middle Aged, Female, Cohort study, Insulin pump, Adult, medicine.medical_specialty, 030209 endocrinology & metabolism, Hypoglycemia, 03 medical and health sciences, Young Adult, Insulin Infusion Systems, Diabetes mellitus, Insulin Pump Therapy, Internal Medicine, medicine, Humans, Hypoglycemic Agents, Glycemic, Advanced and Specialized Nursing, Glycated Hemoglobin, Type 1 diabetes, business.industry, Blood Glucose Self-Monitoring, nutritional and metabolic diseases, medicine.disease, Diabetes Mellitus, Type 1, 24-Month RESCUE Study, Hyperglycemia, Emergency medicine, Real-Time Continuous Glucose Monitoring, Quality of Life, Human medicine, business
الوصف: OBJECTIVEIn recent years, a growing number of people with type 1 diabetes gained access to real-time continuous glucose monitoring (rtCGM). Long-term benefits of rtCGM are unclear because of a lack of large studies of long duration. We evaluated whether real-world rtCGM use up to 24 months offered benefits, particularly in those living with impaired awareness of hypoglycemia (IAH).RESEARCH DESIGN AND METHODSThis 24-month, prospective, observational cohort study followed 441 adults with insulin pumps receiving full reimbursement for rtCGM. Forty-two percent had IAH. The primary end point was evolution of HbA1c, with secondary end points change in acute hypoglycemia complications, diabetes-related work absenteeism, and quality of life scores. Additionally, we evaluated whether people could achieve glycemic consensus targets during follow-up.RESULTSAfter 24 months, HbA1c remained significantly lower compared with baseline (7.64% [60 mmol/mol] vs. 7.37% [57 mmol/mol], P < 0.0001). Sustained benefits were also observed for the score on the hypoglycemia fear survey and hypoglycemia-related acute complications irrespective of hypoglycemia awareness level. People with IAH had the strongest improvement, especially for severe hypoglycemia (862 events in the year before vs. 119 events per 100 patient-years in the 2nd year, P < 0.0001). Over 24 months, more people were able to meet hypoglycemia consensus targets at the expense of slightly fewer people achieving hyperglycemia consensus targets. Furthermore, the number of people with HbA1c CONCLUSIONSUse of rtCGM led to sustained improvements in hypoglycemia-related glucose control over 24 months. Lower fear of hypoglycemia, fewer acute hypoglycemia-related events, and fewer diabetes-related days off from work were observed, particularly in those with IAH.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::913eaa04d022f4d0800a7882e91e5ac3Test
https://pubmed.ncbi.nlm.nih.gov/33067260Test -
5رسالة جامعية
المؤلفون: Massot, Anneleen
المساهمون: LOWYCK, Ine, Massot, Anneleen
وصف الملف: Application/pdf
العلاقة: http://hdl.handle.net/1942/41077Test
الإتاحة: http://hdl.handle.net/1942/41077Test
